Q2 2026 Maravai Life Sciences Holdings LLC Earnings Call

Speaker #1: Hello and welcome, everyone, joining today's MARAVAI LIFESCIENCES Q2, 2026 results earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session.

Speaker #1: To register to ask a question at any time, please press star one on your telephone keypad. Please note this call is being recorded, and we are standing by should you need any assistance.

Speaker #1: It is now my pleasure to turn the meeting over to Deb Hart. Please go ahead.

Speaker #2: Good afternoon, everyone. Thanks for joining us for our second quarter 2026 earnings call. The press release and slides accompanying today's call are available at investors.maravai.com.

Speaker #2: As you can see from the agenda on slide two, our CEO, Bernd Brust, will provide a business update, and our CFO, Raj Asarpota, will review our financial results.

Speaker #2: Dr. Chanfeng Zhao, our Chief Scientific Officer, and Kurt Oreshak, our Executive Vice President and General Counsel, will join us for the Q&A session. Management will make forward-looking statements and refer to gap and non-gap financial measures during today's call.

Speaker #2: Actual results could differ materially from expectations. We will undertake no obligation to update them. We refer you to slide three for details on forward-looking statements and slide four for our use of non-gap financial measures.

Speaker #2: The press release and the slides provide reconciliations to the most directly comparable gap measures and we also post reconciling schedules to our investor website.

Speaker #2: Please also refer to MARAVAI's SEC filings for additional information on risks and uncertainties that may impact our operating results performance and financial condition. Now I'll turn the call over to Bernd.

Speaker #3: Good afternoon, and thank you for joining us. We are very pleased with our second quarter performance, which builds on the strong momentum we established in the first quarter.

Speaker #3: Our results reflect solid execution across the business and reinforce our confidence in both our near-term outlook and long-term strategy. During the quarter, we generated revenue of $51.4 million representing 9% year-over-year growth.

Speaker #3: Skylink revenue increased 12%, driven by strong demand for GMP consumables and continued strength in discovery mRNA. Particularly from larger preclinical programs, building our potential GMP pipeline as customer programs advance into clinical development.

Speaker #3: Because Skylink supports customers throughout the drug development lifecycle, we believe today's discovery success will create tomorrow's GMP opportunity. Sickness also delivered another solid quarter, with revenue growing 3% year-over-year, marking its fifth consecutive quarter of growth.

Speaker #3: Through its industry-leading HCP and ELISA portfolio, combined with expanding analytical services, Sickness continues to provide stable, recurring, high-margin revenue while strengthening the biologics workflow. Our profitability improved significantly—adjusted gross margin expanded more than 1,600 basis points year-over-year to 58.9%, while adjusted EBITDA improved by $19.1 million to $8.7 million.

Speaker #3: These results reflect higher revenue, a favorable product mix, and the benefits of the operating model we've built over the past year. We also significantly strengthened our balance sheet, in June we refinanced our debt, reducing borrowings to approximately $150 million, essentially cutting debt in half since the beginning of 2026, while extending the maturities to 2032.

Speaker #3: Combined with improving profitability, we believe MARAVAI is well positioned from both a liquidity and financial flexibility standpoint. Now let's turn to slide seven, and discuss our progress against our three strategic priorities.

Speaker #3: Innovation, commercial execution, and operational excellence. Innovation. This remains the foundation of our long-term growth strategy. During the quarter, Skylink launched its new GMP-grade enzyme portfolio, expanding our ability to serve customers as a differentiated single-source innovation partner.

Speaker #3: Increasingly, customers are looking for integrated manufacturing solutions rather than individual components. And this launch meaningfully strengthens our competitive position. We also continue to see outstanding adoption of MaTil.

Speaker #3: Just one year after commercial launch, more than 125 customers are now using our technology, including many of the world's leading pharmaceutical companies. Customer adoption continues to accelerate through new accounts, repeat orders, and broader use across multiple applications.

Speaker #3: Later this year, we expect to launch GMP-grade MaTil, extending this platform into clinical manufacturing. Customer interest has been applications, further demonstrating how discovery innovation creates future GMP growth opportunity.

Speaker #3: Sickness also continued to expand its innovation portfolio, through the launch of a new residual prism-a mix and go kit, while continuing to invest in mass spec analytical services.

Speaker #3: Although services have a longer sales cycle, we are encouraged by growing customer engagement and increasing repeat business, and we expect this capability to become a more meaningful contributor over time.

Speaker #3: Finally, we continue strengthening our intellectual property portfolio across CleanCap, MaTil, and Sickness assays. In addition to two new European patents we've received in Q1, during Q2, Skylink received a new China patent, covering a full family of CleanCap capping analogs, further reinforcing our global IP position.

Speaker #3: Commercial execution. Our commercial momentum continued to build throughout the first half of the year. Greater customer engagement has improved forecasting, increased visibility, and strengthened order conversion, and those improvements are clearly reflected in our results.

Speaker #3: Within discovery mRNA, we added 67 new customers in Q2, a record quarter for new customer acquisitions. While our e-commerce platform also delivered record quarterly revenue.

Speaker #3: GMP consumables remained a standout performer, growing 55% year-over-year, driven by large CleanCap clinical orders and our first GMP enzyme order. We had no COVID GMP-related revenue in Q2.

Speaker #3: Operational excellence remains a key driver of our financial performance. The restructuring actions we implemented last year are now largely complete. Combined with our debt refinancing, the company has fundamentally reset its cost structure.

Speaker #3: Importantly, our manufacturing infrastructure is already in place, between our state-of-the-art mRNA facilities, a new operating model is now built to scale, and we can support meaningful future growth with relatively modest incremental fixed costs.

Speaker #3: This operating leverage is central to our long-term financial model. Now let me switch gears for a minute and share how we think about Skylink.

Speaker #3: As part of our recent long-range planning process, we concluded that investors may appreciate greater feasibility into the distinct growth engines within Skylink. While we continue to report and manage our business to two operating segments, Skylink and Sickness, we increasingly think about Skylink through three distinct market categories.

Speaker #3: mRNA, CDMO, and specialty chemistry. mRNA is our largest and most strategically important business out of these three. It spans the full development lifecycle through discovery, clinical trials, and ultimately commercial programs.

Speaker #3: Discovery mRNA, which grew 17% year-over-year in Q2, includes our research-use products such as CleanCap, MaTiL, and related reagents. This spans the full research spectrum, with academic and basic research customers on one end, and biopharma and biotech conducting advanced preclinical screening and program development on the other.

Speaker #3: This business not only generates revenues today, but also seeds future GMP demand. GMP consumables, which grew 55% year-over-year in Q2, is the clinical-grade supply business within mRNA.

Speaker #3: GMP CleanCap, GMP enzymes, and soon GMP MaTil—this is where Skylink's operating leverage becomes most evident. The growth potential for Skylink here is straightforward.

Speaker #3: As customer programs advance through clinical development, we expect their demand for GMP materials to increase significantly. While our infrastructure remains largely unchanged. During the quarter, four new GMP customers.

Speaker #3: More importantly, with additional GMP product launches, we expect to increase the number of products each customer sources from Skylink, deepening relationships and expanding our share of wallet.

Speaker #3: The third stage is commercial programs. To date's revenue consists of COVID-related CleanCap, which you'll recall was $14.3 million in Q1, or approximately 7% of estimated 2026 revenue at the midpoint of guidance.

Speaker #3: Over the longer term, we expect commercial launches from our current non-COVID clinical pipeline to become a meaningful growth advance toward commercialization, expect it to begin around 2028 and 2029.

Speaker #3: We believe Skylink is well positioned to support commercial-scale manufacturing using infrastructure that already exists. Overall, excluding COVID CleanCap, mRNA represents approximately 35% of expected 2026 revenue.

Speaker #3: And we continue to expect this business to grow at high single-digit to low double-digit rates over time. The second component within Skylink is our CDMO business, which represents less than 5% of expected 2026 revenue.

Speaker #3: While project-based and inherently variable, it serves a select group of highly strategic cell and gene therapy customers with programs progressing toward commercialization. Finally, specialty chemistry.

Speaker #3: This is a stable, recurring research tools business consisting of oligo services and reagents, NTPs, and other related reagents. This business represents a little more than 20% of our expected 2026 revenue, while we expect lower growth in mRNA it remains an important contributor with strong customer relationships and attractive profitability.

Speaker #3: To be clear, our external financial reporting remains unchanged. We continue to operate and report through our two segments, Skylink and Sickness. The additional framework we're providing today is intended to help investors better understand the different growth drivers within Skylink, and how they contribute to our long-term opportunity.

Speaker #3: In summary, we delivered another quarter of strong execution. We advanced innovation, strengthened commercial momentum, improved profitability, and significantly enhanced our financial position. Perhaps most importantly, we believe the investments we've made over the past year have fundamentally changed the company's earnings profile.

Speaker #3: Our infrastructure is in place, our balance sheet is stronger, and as customer programs continue advancing from discovery into clinical development, and ultimately commercialization, we believe we are well positioned to deliver attractive, long-term revenue growth, expanding margins, and increasing cash generation.

Speaker #3: With that, I'll turn the call over to Raj to review the financial results and discuss our updated outlook. Raj?

Speaker #2: Thank you, Bernd. Our second quarter reflects solid execution across both segments, with improving margin flow-through. I'll focus on the key drivers behind the quarter, including revenue composition, profitability, and our updated outlook.

Speaker #2: Let me start with the closer look at revenue on slide 10. Our business remains well diversified across end markets. Revenue by customer type was 30% biopharma, 35% life sciences and diagnostics, 5% academia, 7% CRO, CMO, CDMO, and 23% distributors.

Speaker #2: By geography, revenue was 62% North America, 20% EMEA, 11% Asia Pacific excluding China, and 7% in China. Turning to slide 11, our gap net loss before non-controlling interest was 21.6 million.

Speaker #2: This compares to a gap net loss before non-controlling interest of $69.8 million in the prior year period. Adjusted EBITDA on non-gap measure was 8.7 million for Q2, exceeding our expectations and improving by more than 19 million year-over-year.

Speaker #2: This was driven by stronger revenue, favorable mix toward high-margin GMP, and mRNA discovery, as well as continued opex discipline. Basic and diluted loss per share in Q2 was $0.08, compared to a loss of $0.27 per share in Q2 2025.

Speaker #2: Adjusted EPS was a loss of $0.02, compared to a loss of $0.08 per share last year. Moving to the balance sheet and other financial metrics on slide 12, as Bernd mentioned, in early June we significantly reduced debt and refinanced our term loan, extending the maturity out to 2032.

Speaker #2: We ended the quarter with $70.1 million in cash and in debt. Depreciation and amortization was $11.8 million, net interest expense was $3.7 million, and stock-based compensation on non-cash charge was $10.2 million for the quarter.

Speaker #2: Turning to segment performance on slide 13, Skylink represented 67% of total revenue in the quarter, and contributed $7 million of adjusted EBITDA benefiting from high-margin GMP product mix and improved operating leverage.

Speaker #2: This represents an improvement of more than 14.2 million year-over-year. Within Skylink, mRNA and specifically the GMP consumables and discovery mRNA categories were the primary growth drivers.

Speaker #2: Specialty chemistry was steady, CDMO was down year-over-year, and in line with our expectations, based on the timing of customer programs. Sickness represented 33% of total revenue and continued to deliver strong profitability.

Speaker #2: Sickness generated $11.4 million of adjusted EBITDA with margins of 68%. Sickness saw steady demand for HCP and ELISA kits, and strength in China due to distributor ordering timing.

Speaker #2: Corporate expenses impacting adjusted EBITDA were $9.7 million in the quarter. These expenses include HR, finance, legal, IT, and public company costs. Turning to our guidance on slide 14, we are maintaining our expected 2026 revenue range of $205 million to $215 million representing growth of 10% to 16% over 2025.

Speaker #2: We expect Skylink to grow in the high teens driven by continued strength in GMP and discovery mRNA consumables. For Sickness, we continue to expect low to mid-single-digit growth.

Speaker #2: We are raising our full-year adjusted EBITDA guidance to $33 to $35 million, representing an improvement of 64 to 66 million year-over-year primarily driven by improved performance in continue to see strong demand and higher margin areas of the portfolio, including GMP consumables, our high-margin mRNA discovery consumables, and key Sickness product lines.

Speaker #2: That mix shift combined with the structural improvements we've made is driving the outperformance in EBITDA. Additionally, we see further upside in gross margin expansion and now expect greater than $1,400 basis points of improvement, supported by restructuring actions, cost discipline, favorable product mix, and a strong first half of the year.

Speaker #2: The remainder of the guidance framework provided in our Q1 call is unchanged. The adjusted EBITDA guidance raise reflects higher confidence in profitability expectations rather than a change in our prudent revenue assumptions.

Speaker #2: We are maintaining the expected revenue range because two meaningful parts of our business, CDMO and large GMP consumables orders, are program-driven by nature. Individual orders can be large and their timing can vary meaningfully quarter to quarter, it's simply how these businesses work, and our range is sized to reflect it.

Speaker #2: Overall, we are encouraged by the momentum in the business, improved commercial execution of more efficient cost structure, and favorable mix are driving meaningful financial progress, and we remain confident in our outlook for 2026 and increasingly excited by the longer-term commercial opportunity Bernd described.

Speaker #2: With that, I'll turn the call back over to the operator for Q&A.

Speaker #1: Thank you. If you'd like to ask a question, press star 1 on your keypad. To leave the Q at any time, press star 2.

Speaker #1: In the interest of time, we do ask that you please limit yourself to one question and one follow-up. Once again, that is star 1 to ask a question.

Speaker #1: And we'll take our first question from Matt Stanton, with Jefferies. Please go ahead. Your line is open.

Speaker #3: Hey, thanks. Maybe first one just on the guide. I think you talked about it as as being prudent and obviously there's a lumpy part of the business, but you did a little over $100 million for the base business in first half, back half seems to imply that steps down closer to a run rate of mid-40s per quarter from the low 50s you did in the first half.

Speaker #3: Just talk about kind of line of sight into that, any areas of potential conservatism there as we think about the back half guide, some of the timing dynamics due to projects you talked about.

Speaker #3: And then, can you remind us what you’re penciling in for the GMP mod tail and the back half of the year, and then also anything for the recent enzyme launch as well?

Speaker #3: Thanks.

Speaker #4: I'll let Matt, this is Bernd. I'll let Raj answer most of that as far as the guidance is concerned. I mean, Q3 inherently is a lower revenue quarter.

Speaker #4: In this business, so that's what you're dealing with. Certainly in the second half of the year, and the reality is we grew, I think our GMP business 55% in the second quarter, which is obviously unusual number.

Speaker #4: No COVID in there whatsoever. And you just have some variability here. There's a couple of larger deals out there still of business our size, a couple hundred million bucks, since you have it's not unusual to have multi-million dollar type of orders in there.

Speaker #4: It just unfortunately shifts between quarters at times. There's a couple of deals out there that we'll see where they come in this year or next year, and we'll adjust it accordingly at that point.

Speaker #4: But we want to be just careful in how we position that.

Speaker #5: Raj, do you want to take.

Speaker #3: And then enzyme?

Speaker #5: Yeah, I have to—actually, just before we go there. So I think, like Bernd mentioned, in the second half cadence, and like I said in my prepared remarks, our range has a couple of meaningful parts of the business—both CDMO and large GMP—which are more program-driven by nature.

Speaker #5: So these orders can be very large, like Bernd said, and the timing is can vary meaningfully quarter over quarter. So that's just simply how they work.

Speaker #5: And what we're doing is giving you a prudent guide based on where we see these how this changes, but really kind of the timing sits with our customers' program schedules, rather than with us.

Speaker #5: So our practice is not to assume those orders until we can see them. So I'll just kind of want to emphasize that. And Matt, you had another question on mod tail.

Speaker #5: Could you repeat that?

Speaker #3: Just if you're penciling in anything in the back half of the year for both the GMP mod tail and then also the recent enzyme launch.

Speaker #4: No GMP mod tail in the second half of the year. No, we will release our GMP mod tail in the second half of this year, but we don't expect orders until 2027 for that.

Speaker #4: Enzymes is launch. Yeah, enzymes we have our first enzymes order shipped, in fact, but mod tail, it's a little bit too early, right? It's been about a year now since we launched that.

Speaker #4: It's been a great uptick, 125 or so customers so far. And we expect some of that to hit a GMP requirement sometime next year, but first step is for us to make it as a GMP quality product and then sell it in 2027.

Speaker #3: Okay, thanks. And then appreciate the caller on the kind of subsegments within TriLink. Just would love kind of your view on you talked about TriLink having potential for higher growth and maybe some upside the drivers of that.

Speaker #3: It sounds like maybe the commercial programs are more 2028, 2029. Earlier biotech funding coming on—maybe that's earlier, and we see upside there. Some of these bigger product launches taking hold—just, how do we think about the midterm upside drivers, relative to some of the color you gave in terms of the five-year CAGRs for the subsegments?

Speaker #3: Thanks.

Speaker #4: I think one of the most positive signs in our business that we're seeing incredible uptick into discovery world, right? And at all levels, basic research as well as into later-stage clinical trials or preclinical trials.

Speaker #4: So, the fact that that business is growing materially and we see continued growth there should certainly lead to more GMP opportunities as those programs progress.

Speaker #4: And so I think short-term, that's where we look at. And again, all the indicators are positive there. So on the commercialization front, yeah, obviously we don't control the speed of what that moves.

Speaker #4: Those are customer programs and our customers that are driving that. But from what we see, we expect that sort of in 2027, 2028 to take place.

Speaker #5: Yeah, maybe I'll add a little bit more there. And I think in the near term, we expect trialing to grow at high single-digit rate.

Speaker #5: And then it's really, again, driven by discovery and GMP consumables. And as clinical programs convert into commercial supply, we expect that to move to low double-digit rate.

Speaker #5: And then mod tail is a lever layered on top of that that can really create an inflection point for the business. So the commercial conversion here is a mixed story.

Speaker #5: Which is why we expect margin expansion to also accompany this revenue growth.

Speaker #3: Super. Thank you.

Speaker #1: Matt?

Speaker #2: Thank you. We'll take our next question from Zubu Nambi with Guggenheim. Please go ahead. Your line is open.

Speaker #6: Hi, this is Ricky Ohm for Zubu. Thanks for taking our question. Wondering if you could share anything about Mach-V growth in the quarter and previously you've had some comments around positive regulatory feedback and the potential for this to replace traditional viral clearance studies.

Speaker #6: Do you expect any guidance from regulators or any endorsement that could potentially accelerate adoption there? And maybe just how should we think about its contribution to the Cygnus growth this year and next year?

Speaker #6: Thank you.

Speaker #3: I'll take that, Raj.

Speaker #5: Yeah, we don't really give the Mach-V growth rates, but it's a small base and is continuing to grow. And contribute to Cygnus's growth profile.

Speaker #5: In terms of regulatory, it's just a little too early to get any intel on that.

Speaker #2: Thank you. We'll take our next question from Matt Hewitt with Craig Hallam Capital Group.

Speaker #7: Good afternoon. Thanks for taking the questions. Maybe first up, congratulations on the record quarter with the new online strategy. I'm just curious, how that's kind of playing out relative to your expectations and how we should think about that ramp over the course of this year into next year.

Speaker #4: I'll maybe give a higher level answer to this than Raj may make some specific statistics on that. I mean, the short answer is it's going much better than we even had anticipated the adoption is incredible.

Speaker #4: The number of orders and revenues flowing through now without really any human interaction is pretty significant now. This largely happens in a smaller discovery world, of course.

Speaker #4: It's so many places a half-million-dollar order. It's hard to kind of assume e-commerce takes that over. But when you look at what we are currently seeing, the largest uptick of orders coming through in TriLink come all through our e-commerce platforms.

Speaker #7: That's excellent. And I think oops, go ahead.

Speaker #5: No, I was just going to add to what Bernd said, just in terms of top-line growth. This whole e-commerce AI strategy is improving our ordering automation.

Speaker #5: We've got a lot more data-driven customer engagement and predictive analytics. So that's going to produce thing into nice commercial opportunities.

Speaker #4: We shared with you I think 60 some new customers in the second quarter. A lot of this is driven through e-commerce.

Speaker #7: That's great. That's great. And then out of curiosity, so you noted that the clean cap patent that you received during the quarter, how important was that to, I guess, going after that market in a bigger way?

Speaker #7: Having that patent protection behind you, was that something that was critical and now you kind of put your foot on the gas? Or were you already kind of going after that market hard and this is just kind of provides a little bit of protection behind the scenes?

Speaker #5: I think the new patent is evidence of the strength of our patent portfolio around the world. I think we are still the business in China at the moment is still small, but is a focus of ours as that market continues to develop.

Speaker #7: Understood. Thank you.

Speaker #2: Thank you. And as a quick reminder, if you'd like to ask a question, you may press star one now. We'll take our next question from Matt LaRue with William Blair.

Speaker #2: Please go ahead. Your line is open.

Speaker #3: Hi. Thanks for the questions. This is Jacob Cramble on for Matt. So I guess just want to start on the guide, just a quick one.

Speaker #3: I know it's kind of been touched on, but I just wanted to confirm that the rationale behind not raising it is just purely prudence and not really related to any nuances and market demand and customer behavior, customer orders slowing or anything around that and really just prudence and understand the or appreciate the fact that you're not including any of the big or your business is susceptible to the big lumpy orders quarter to quarter and really just don't want to include that.

Speaker #3: So yeah, I guess just wanted to confirm.

Speaker #4: That's absolutely true. And I would even add to that, when you look at our run rate business, sort of small to midsize orders, we see significant growth there.

Speaker #4: And so the revenue guidance we're talking about here is purely driven by larger order orders that are purely tied to customer projects. They're not competitive.

Speaker #5: Yeah, if you look at all the like I may have mentioned before, the underlying demand indicators, whether it's new customer asset, Bernd talked about, or our GMP consumables growth, the e-commerce, all of those indicators improved in Q2.

Speaker #5: So, it's really just a function of the variability, more than anything else.

Speaker #3: Okay, that makes sense. And then, yeah, I also appreciate the new disclosures around TriLink breaking out the three sub-segments. It's very helpful. I know you mentioned the external financial reporting hasn't changed or anything, but I was just wondering if these are areas you plan to continue updating the investor community on a quarterly basis.

Speaker #3: And kind of I know the base TriLink business has now grown double digits for three straight quarters, which is also very good to see.

Speaker #3: But just wondering if you can kind of touch on what's driving the improved performance and kind of the sustainability growth here. Is it just as simple as the improved execution and commercial rigor coinciding with improving end markets or is there something else there?

Speaker #4: I think you touched on all of it. I mean, yes, the intent is to continue to report and give this visibility to the investment base that we have.

Speaker #4: And yeah, I mean, demand is certainly up. The markets are getting stronger. I think our execution is materially better than it has been in the past.

Speaker #4: I think our new product and technologies coming to market are helping growth. So I think all those pieces together, the sustainability of that growth in TriLink, we feel good about.

Speaker #4: I think when you look specifically at our CDMO and our GMP business, we talk about it a lot. This is a lumpiness that is just simply the nature of that business.

Speaker #4: And that has nothing to do with market demand. In fact, our number of clinical trials are growing. We're almost close to 50 customers now, I think, in clinical trials.

Speaker #4: Each of those customers represents somewhere between two and three programs so the volume of customers moving are healthy and so we feel really good about the underlying markets and how we are positioned in there.

Speaker #2: Thank you. We'll take our next question from Matthew Parisy with KeyBank Capital Markets. Please go ahead, your line is open.

Speaker #6: Hi, yes. This is Matthew Parisy. I'm from Palm Night at KeyBank Capital Markets. You highlighted the incredible uptick in discovery and I was wondering if you're seeing that come through from the improved biotech funding or is that improved funding not really translating through revenue yet?

Speaker #4: I think funding in general is improving in the segments where we play. And so there's no question that that's helping out. If you look at the last few years, obviously, it's been one of the toughest cycles in the market segment that we find ourselves.

Speaker #4: But that certainly is showing a rebound here to the fact that we're seeing growth not just in the later-stage clinical trials, but also basic research is a really good indicator for us.

Speaker #6: I appreciate the insight. And then last quarter, you flagged that you expected nine customers to transition to GMP throughout '26 with two already converting.

Speaker #6: I'm wondering if that nine still holds and then if you've seen any convert into Q.

Speaker #4: Yeah. So we're at six now. We added four in the second quarter. And so yeah, we see the nine for the three remainder for the year that should be obtained.

Speaker #6: I appreciate the insight, and thanks for the questions. Congrats again on the great quarter.

Speaker #4: Thank you.

Speaker #5: Thanks.

Speaker #2: Thank you. We'll take our next question from Dan Arias with Staples. Please go ahead. Your line is

Speaker #1: Open .

Speaker #2: Hey , guys , this is Rohan . On for Dan . Thanks for the questions It looks like Montel went from more than 70 customers in the first quarter to more .

Speaker #2: More than 125 in Q2 within a year since launch . If you convert that to dollars , what did Montel contribute this quarter of the 125 customers have requested , GMP material .

Speaker #2: Thanks .

Speaker #3: Well , we won't break out the dollar value for for Montel , this is one one level too low as far as what number of customers ?

Speaker #3: A few customers have requested GMP material . I don't know , Roger . Exact number for that , but we expect that there's some number of customers that are going to request GMP material in in 2024 , 2027 .

Speaker #3: We'll be ready . Sometime later this year to have that material available .

Speaker #2: Okay . Thanks . And you know how much of sicknesses to . Sorry , how much of the 2026 and 2027 revenue plan comes from products launched in the last 24 months ?

Speaker #2: I'm trying to figure out whether the innovation pipeline is genuinely additive or substituting for legacy Cleancap dollars . Thanks .

Speaker #3: Was the question

Speaker #4: Yeah , I .

Speaker #2: Think sorry , this is just the overall product . This is overall product question within the pipeline . Sorry .

Speaker #3: Yeah . We're not going to break down revenues coming from new products . I mean mocktail is obviously a driver there . And then some things within Cygnus on services are big drivers or will become bigger drivers .

Speaker #3: And so we're not specifically going into what revenues are coming from newly introduced products.

Speaker #2: Okay . Thank .

Speaker #5: You

Speaker #1: Thank you . We'll take our next question from Jason Brow of Bowers with Deutsche Bank . Please go ahead . Your line is open .

Speaker #6: Hi . Good afternoon . So just curious what the funnel looks like for GMP . Is there a potential for upside to that ?

Speaker #6: Benign customers for this year ? I mean you had you were at six now . And do you have visibility into 2027 on GMP .

Speaker #3: Well, certainly there is an opportunity for upside, right? As we talk about being prudent on our revenue, because these things can be rather big.

Speaker #3: That means you can , you know , have some see some delays , but you can also see some things happening . we , we like our funnels .

Speaker #3: They're growing steadily and , and so , you know , from that perspective , we feel good about where that business is heading .

Speaker #3: We're not giving guidance yet on 27 yet on , on what the new incremental customers will be . But I will say where we're seen really throughout this year , we've seen really nice performance in this larger discovery world where that kind of really indicates people getting ready for clinical trials .

Speaker #3: These are very large preclinical orders , and we've seen nice movement there . And so we feel good about where where that funnel is heading .

Speaker #3: And and so there's no nothing we see today that would indicate that that's not going to continue to grow

Speaker #6: Appreciate it . And then just on the other end of the spectrum , how about uptake of the e-channel , how that's trending and how that's performing versus sort of what your expectations were when you changed the commercial strategy there ?

Speaker #3: Yeah . I mean , it's doing really well . When you look at the new number of customers , we mentioned sort of in the mid 60s this quarter , that's primarily coming from this earlier stage , basic research worlds .

Speaker #3: There's some exception to that , but the majority are new customers . And a lot of those are acquired through our e-commerce capabilities these days .

Speaker #3: And with that , we're starting to see nice growth , right ? When you look at the basic research segments up until really , you know , six months ago , that was a struggling market .

Speaker #3: And , and we've seen a nice rebound there , both market funding as well as our ability to acquire those customers . And certainly Monteil is not hurting there either .

Speaker #3: We're seeing a big uptick in that world of people trying, Mateo, with their mRNA experiments.

Speaker #6: Understood . Appreciate the questions .

Speaker #4: Thanks , Justin .

Speaker #1: Thank you . This does conclude our question and answer session . I would like to now turn the conference back to Bernd Brust for any closing or additional remarks .

Speaker #3: All right . Well , thanks everyone . We appreciate the time here . You know , we keep on loving where this business is going , right ?

Speaker #3: Trialing grew 12% year over year . Great strength in the mRNA business , both in in GMP consumables as well as discovery . I'm glad everybody appreciate the the other insights we're giving in this business to really understand where growth sits within the Trilink business .

Speaker #3: Cygnus remains stable. Right. It's 3% year over year. We've always said mid-single digits; that business is on track for hitting plan this year.

Speaker #3: We should see a little bit more growth in the second half . But but generally that business is performing the way we expect it to .

Speaker #3: Another great quarter of execution . Right ? Great innovation . Really , really good commercial momentum , both from a large deals and the commercial teams in the field to the e-commerce capabilities that we really have brought on board here .

Speaker #3: Our profitability continues to get better . There's not been that many questions on this here , but our financial position really has been significantly at hands .

Speaker #3: When you look at us recapping the business , our cash position is absolutely amazing . We're good . Till in the early 30s now .

Speaker #3: And you know , if you're looking at the long term outlook of this business , we're great growth in , in , in research as well as clinical trials .

Speaker #3: But as that evolves into commercial , having that balance sheet in place gives us a lot of confidence that we're in here . And , and will work this for many years to come and see a growth coming or see our growth getting to where we want it to be .

Speaker #3: When you have multiple commercial programs going , going live . So we feel confident about the business . We like the quarter , we feel good about the rest of the year .

Speaker #3: We feel great about the long term future of the company . We appreciate everybody's time here and we'll speak to you again next quarter